{"nctId":"NCT01911780","briefTitle":"Compare Efficacy and Safety of Telmisartan/Hydrochlorothiazide With Telmisartan/Hydrochlorothiazide Plus Amlodipine","startDateStruct":{"date":"2013-07"},"conditions":["Hypertension"],"count":132,"armGroups":[{"label":"telmisartan + HCTZ + amlodipine","type":"EXPERIMENTAL","interventionNames":["Drug: telmisartan + HCTZ","Drug: amlodipine"]},{"label":"telmisartan + HCTZ + placebo","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: placebo","Drug: telmisartan + HCTZ"]}],"interventions":[{"name":"placebo","otherNames":[]},{"name":"telmisartan + HCTZ","otherNames":[]},{"name":"telmisartan + HCTZ","otherNames":[]},{"name":"amlodipine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n1. Essential hypertensive patients who have already taking 2 or 3 antihypertensive drugs and mean seated diastolic blood pressure (DBP) must be \\>=90 and \\<=114 mmHg and mean seated systolic blood pressure (SBP) must be =\\<200 mmHg\n2. Able to stop all current antihypertensive drugs (other than study medication) from Visit 1b through the end of the trial without risk to the patient based on the investigator's opinion\n3. Age 20 years or older\n\nExclusion criteria:\n\n1. Patients with known or suspected secondary hypertension\n2. Patients with clinically relevant cardiac arrhythmia\n3. Congestive heart failure with New York Heart Association (NYHA) functional class III-IV\n4. Patients with recent cardiovascular events\n5. Patients with recent stroke events\n6. Patients with a history of sudden deterioration of renal function with angiotensin II receptor blockers or angiotensin converting enzyme inhibitors; or patients with post-renal transplant or post-nephrectomy\n7. Patients with hepatic and/or renal dysfunction\n8. Pre-menopausal women who are nursing or pregnant","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","maximumAge":"100 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Mean Seated DBP at Trough After 8 Weeks of the Double-blind Period.","description":"Change from baseline in mean seated diastolic blood pressure (DBP) at trough (24-hour post dosing) after 8 weeks of the double-blind period. The results are presented as 'change' rather than 'reduction' i.e., reductions are expressed with negative values'. The 'adjusted mean' is shown as 'mean'.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.8","spread":"0.8"},{"groupId":"OG001","value":"-1.3","spread":"0.8"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Mean Seated SBP at Trough After 8 Weeks of the Double-blind Period.","description":"Change from baseline in mean seated systolic blood pressure (SBP) at trough after 8 weeks of the double-blind period. The results are presented as 'change' rather than 'reduction' i.e., reductions are expressed with negative values'. The 'adjusted mean' is shown as 'mean'.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.6","spread":"1.4"},{"groupId":"OG001","value":"-2.1","spread":"1.5"}]}]}]},{"type":"SECONDARY","title":"The Percentage of Patients With DBP<90 mmHg and SBP<140 mmHg Blood Pressure at Trough After 8 Weeks of Double-blind Period.","description":"The percentage of patients with DBP\\<90 mmHg and SBP\\<140 mmHg as seated blood pressure at trough after 8 weeks of the double-blind period. The results are presented as 'change' rather than 'reduction' i.e., reductions are expressed with negative values'. The 'adjusted mean' is shown as 'mean'.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.8","spread":null},{"groupId":"OG001","value":"21.9","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Patients With DBP<90 mmHg and SBP<140 mmHg Blood Pressure at Trough After 52 Weeks of Extension Period.","description":"The number of patients with DBP\\<90 mmHg and SBP\\<140 mmHg as seated blood pressure at trough after 52 weeks of the extension period. Note, week 52 of the extension period corresponds to 60 weeks after the reference baseline.\n\nThe results are presented as 'change' rather than 'reduction' i.e., reductions are expressed with negative values'. The 'adjusted mean' is shown as 'mean'.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Mean DBP Pressure at Trough After 52 Weeks of the Extension Period.","description":"Change from baseline in mean seated diastolic blood pressure at trough after 52 weeks of the extension period. Note, week 52 of the extension period corresponds to 60 weeks after the reference baseline.\n\nThe results are presented as 'change' rather than 'reduction' i.e., reductions are expressed with negative values'. The 'adjusted mean' is shown as 'mean'.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.4","spread":"1.0"},{"groupId":"OG001","value":"-10.0","spread":"1.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.9","spread":"1.0"},{"groupId":"OG001","value":"-10.5","spread":"1.0"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Mean Seated SBP at Trough After 52 Weeks of the Extension Period.","description":"Change from baseline in mean seated systolic blood pressure at trough after 52 weeks of the extension period. Note, week 52 of the extension period corresponds to 60 weeks after the reference baseline.\n\nThe results are presented as 'change' rather than 'reduction' i.e., reductions are expressed with negative values'. The 'adjusted mean' is shown as 'mean'.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.8","spread":"1.6"},{"groupId":"OG001","value":"-14.3","spread":"1.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.6","spread":"1.3"},{"groupId":"OG001","value":"-15.9","spread":"1.4"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":68},"commonTop":["Nasopharyngitis","Upper respiratory tract inflammation"]}}}